Brokerages Expect CRISPR Therapeutics AG (NASDAQ:CRSP) Will Post Quarterly Sales of $4.23 Million

Wall Street analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) will report sales of $4.23 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for CRISPR Therapeutics’ earnings. The lowest sales estimate is $200,000.00 and the highest is $14.80 million. CRISPR Therapeutics posted sales of $900.70 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 99.5%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that CRISPR Therapeutics will report full year sales of $187.03 million for the current year, with estimates ranging from $1.00 million to $940.00 million. For the next fiscal year, analysts forecast that the business will post sales of $231.76 million, with estimates ranging from $3.37 million to $727.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The firm had revenue of $0.94 million during the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. CRISPR Therapeutics’s quarterly revenue was up 74.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.51) EPS.

CRSP has been the subject of a number of analyst reports. Truist Financial reiterated a “buy” rating and issued a $220.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 16th. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. SVB Leerink dropped their target price on shares of CRISPR Therapeutics from $126.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, February 16th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $171.00 to $168.00 in a report on Tuesday, May 10th. Finally, Barclays dropped their target price on shares of CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $121.60.

CRISPR Therapeutics stock opened at $56.34 on Friday. The firm has a 50-day moving average of $58.69 and a 200-day moving average of $66.48. The company has a market cap of $4.36 billion, a price-to-earnings ratio of 15.61 and a beta of 2.05. CRISPR Therapeutics has a one year low of $42.51 and a one year high of $169.76.

Several hedge funds have recently made changes to their positions in the stock. Capital International Sarl lifted its stake in shares of CRISPR Therapeutics by 20.0% during the 1st quarter. Capital International Sarl now owns 24,189 shares of the company’s stock valued at $1,518,000 after buying an additional 4,027 shares in the last quarter. Capital International Investors lifted its stake in shares of CRISPR Therapeutics by 0.3% during the 1st quarter. Capital International Investors now owns 3,602,152 shares of the company’s stock valued at $226,107,000 after buying an additional 10,992 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of CRISPR Therapeutics by 106.0% during the 1st quarter. Virtu Financial LLC now owns 22,401 shares of the company’s stock valued at $1,406,000 after buying an additional 11,525 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $220,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $5,176,000. Institutional investors own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.